A PYMNTS Company

Innovation Markets after Genzyme/Novazyme

BY | July 17, 2008

This article is part of a Chronicle. See more from this Chronicle Richard Gilbert, Jul 12, 2008 The U.S. Federal Trade Commission alleged adverse effects on innovation in about forty…

This article is part of a Chronicle. See more from this Chronicle

Richard Gilbert, Jul 12, 2008

The U.S. Federal Trade Commission alleged adverse effects on innovation in about forty percent of all merger challenges between 1996 and mid-2008. The percentage was much higher for challenges in industries with unusually high research and development intensity, such as pharmaceuticals (excluding generics), chemicals, software, instruments, high-tech manufacturing, defense, and aerospace. The FTC chal

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 34.239.151.124

Please verify email or join us to access premium content!